Oral Immunotherapy with Human Secretory IgA Improves Survival in the Hamster Model of Clostridioides difficile Infection.
Document Type
Article
Publication Date
10-28-2021
Publication Title
Journal of Infectious Diseases
Abstract
Co-administration of human secretory IgA (sIgA) together with subtherapeutic vancomycin significantly enhanced survival in the Clostridioides difficile infection (CDI) hamster model . Vancomycin (5 or 10 mg/kgx5 days) + healthy donor plasma sIgA/monomeric IgA (TIDx21 days) or hyperimmune sIgA/monomeric IgA (BIDx13 days) enhanced survival of CDI hamsters. Survival curves were significantly improved compared to vancomycin alone (p=0.018 and 0.039 by log-rank (Mantel-Cox) for healthy, and hyperimmune, sIgA, respectively. Passive immunization with sIgA made with recombinant human secretory component and IgA dimer/polymer from pooled human plasma can be administered orally, and prevents lethal infection in a partially treated CDI hamster model.
Volume
224
Issue
8
First Page
1394
Last Page
1397
Recommended Citation
Chiari EF, Weiss W, Simon MR, Kiessig ST, Pulse M, Brown SC, Gerding HR, Mandago M, Gisch K, von Eichel-Streiber C. Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection. J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087. PMID: 33588433; PMCID: PMC8557658.
DOI
10.1093/infdis/jiab087
ISSN
1537-6613
PubMed ID
33588433